Search results
Showing 8566 to 8580 of 8912 results
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]
Discontinued Reference number: GID-HST10038
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
Discontinued Reference number: GID-HST10004
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
Discontinued Reference number: GID-MT117
Discontinued Reference number: GID-MT163
Discontinued Reference number: GID-MT130
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.